Therapeutic Use of Cytoprotective Agents in Canine and Feline Hepatobiliary Disease

Veterinary Clinics of North America - Small Animal Practice

Volumn 39, Issue 3, 2009, Pages 631-652

  Webster, Cynthia R L ^a   Cooper, Johanna ^b  

^a TUFTS UNIVERSITY   (United States)

^b Tufts VETS   (United States)

Author keywords

Glutathione; N acetylcysteine; S adenosylmethionine; Silymarin; Ursodeoxycholate; Vitamin E

Indexed keywords

ACETYLCYSTEINE; ACTIGAL; ALPHA TOCOPHEROL; CATALASE; CYCLOSPORIN; DENOSYL SD4; GLUTATHIONE; GLUTATHIONE PEROXIDASE; LBD 1016; PLACEBO; PREDNISONE; S ADENOSYLMETHIONINE; SILIBININ PHOSPHATIDYLCHOLINE COMPLEX; SILYMARIN; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; VETOQUINOL; ZENTONIL;

ALCOHOL LIVER CIRRHOSIS; ALCOHOL LIVER DISEASE; ALZHEIMER DISEASE; ANGIONEUROTIC EDEMA; ANTIOXIDANT ACTIVITY; BILE DUCT OBSTRUCTION; BLOOD CLOTTING DISORDER; BLOOD PRESSURE; BONE DEMINERALIZATION; BRONCHOSPASM; CAT DISEASE; CHOLANGITIS; CHOLECYSTITIS; CHRONIC HEPATITIS; CLINICAL TRIAL; CYSTIC FIBROSIS; DIARRHEA; DOG DISEASE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG ERUPTION; DRUG EXCRETION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG TISSUE LEVEL; DRUG TOLERABILITY; FATTY LIVER; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HEINZ BODY ANEMIA; HEPATITIS C; HEPATOBILIARY DISEASE; HUMAN; HUNTINGTON CHOREA; INTOXICATION; INTRAHEPATIC CHOLESTASIS; LIPIDOSIS; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FAILURE; LIVER INJURY; LIVER ISCHEMIA; LIVER METABOLISM; LIVER NECROSIS; LIVER PROTECTION; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; MUCOCELE; MUSHROOM POISONING; NITROSATIVE STRESS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PRIMARY BILIARY CIRRHOSIS; PRURITUS; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; VIRUS HEPATITIS; VITAMIN K DEFICIENCY;

ACETYLCYSTEINE; ANIMALS; ANTIOXIDANTS; BILIARY TRACT DISEASES; CAT DISEASES; CATS; CHOLAGOGUES AND CHOLERETICS; CRYOPROTECTIVE AGENTS; DOG DISEASES; DOGS; FREE RADICAL SCAVENGERS; LIVER DISEASES; S-ADENOSYLMETHIONINE; SILYMARIN; URSODEOXYCHOLIC ACID; VITAMIN E;

ANIMALIA; FELIDAE;

EID: 67649406205     PISSN: 01955616     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cvsm.2009.02.002     Document Type: Review

References (94)

1. Vitaglione P., Morisco F., Caporaso N., et al. Dietary antioxidant compounds and liver health. Crit Rev Food Sci Nutr 44 (2004) 575-586
2. Medina J., and Moreno-Otero R. Pathophysiological basis for antioxidant therapy in chronic liver disease. Drugs 65 (2005) 2445-2461
3. Center S. Metabolic, antioxidant, nutraceutical, probiotic, and herbal therapies relating to the management of hepatobiliary disorders. Vet Clin North Am Small Anim Pract 34 (2004) 67-172
4. Beuers U. Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol 3 (2006) 318-328
5. Flatland B. Botanicals, vitamins, and minerals and the liver: therapeutic applications and potential toxicities. Comp Contin Educ 25 (2003) 514-524
6. Pradhan S.C., and Girish C. Hepatoprotective herbal drug, silymarin, from experimental pharmacology to clinical medicine. Indian J Med Res 124 (2006) 491-504
7. Mato J.M., and Lu S.C. Role of S-adenosyl-L-methionine in liver health and injury. Hepatology 45 (2007) 1306-1312
8. Fogden E., and Neuberger J. Alternative medicines and the liver. Liver Int 23 (2003) 213-220
9. Levy C., Seeff L.D., and Lindor K.D. Use of herbal supplements for chronic liver disease. Clin Gastroenterol Hepatol 2 (2004) 947-956
10. Verma S., and Thuluvath P.J. Complementary and alternative medicine in hepatology: review of the evidence of efficacy. Clin Gastroenterol Hepatol 5 (2007) 408-416
11. Dhiman R.K., and Chawla Y.K. Herbal medicines for liver diseases. Dig Dis Sci 50 (2005) 1807-1812
12. Hanje A.J., Fortune B., Song M., et al. The use of selected nutrition supplements and complementary and alternative medicine in liver disease. Nutr Clin Pract 21 (2006) 255-272
13. Malhi H., and Gores G.J. Cellular and molecular mechanisms of liver injury. Gastroenterologist 134 (2008) 1641-1654
14. Akazawa Y., and Gores G.J. Death receptor mediated liver injury. Semin Liver Dis 27 (2007) 327-338
15. Lu S. Regulation of hepatic glutathione synthesis: current concepts and controversies. FASEB J 13 (1999) 1169-1183
16. Meister A., and Anderson M.E. Glutathione. Annu Rev Biochem 52 (1983) 711-760
17. Garcia-Ruiz C., and Fernandez-Checa J.C. Mitochondrial glutathione: hepatocellular survival-death switch. J Gastroenterol Hepatol 21 Suppl 3 (2006) S3-S6
18. Bowry V.W., Ingold K.U., and Stocker R. Vitamin E in human low-density lipoprotein: when and how this antioxidant becomes a pro-oxidant. Biochem J 288 (1992) 341-344
19. Lieber C.S. S-adenosyl-L-methionine: its role in the treatment of liver disorders. Am J Clin Nutr 76 (2002) 1183S-1187S
20. Martinez-Chantar M.L., Garcia-Trevijano E.R., Latasa M.U., et al. Importance of a deficiency in S-adenosyl-L-methionine synthesis in the pathogenesis of liver injury. Am J Clin Nutr 76 (2002) 1177S-1182S
21. Avila M.A., Garcia-Trevijano E.R., Martinez-Chantar M.L., et al. S-adenosylmethionine revisited: its essential role in the regulation of liver function. Alcohol 27 (2002) 163-167
22. Ara A.I., Xia M., Ramani K., et al. S-adenosylmethionine inhibits lipopolysaccharide-induced gene expression via modulation of histone methylation. Hepatology 47 (2008) 1655-1666
23. Webster C.R., Boria P., Usechak P., et al. S-adenosylmethionine and cAMP confer differential cytoprotection against bile acid-induced apoptosis in canine renal tubular cells and primary rat hepatocytes. Vet Ther 3 (2002) 474-484
24. Ansorena E., Berasain C., López Zabalza M.J., et al. Differential regulation of the JNK/AP-1 pathway by S-adenosylmethionine and methylthioadenosine in primary rat hepatocytes versus HuH7 hepatoma cells. Am J Physiol Gastrointest Liver Physiol 290 (2006) G1186-G1193
25. Dey A., Caro A.A., and Cederbaum A.I. S-adenosylmethionine protects ob/ob mice from CYP2E1-mediated liver injury. Am J Physiol Gastrointest Liver Physiol 293 (2007) G91-G103
26. Frezza M., and Terpin M. The use of S-adenosylmethionine in the treatment of cholestatic disorders: a meta-analysis of clinical trials. Drug Invest 4 (1992) 101-108
27. Manzillo G., Piccinio F., Surrenti C., et al. Multicentre double blind placebo controlled study of intravenous and oral S-adenosyl-l-methionine in cholestatic patients with liver disease. Drug Invest 4 (1992) 90-100
28. Mato J.M., Camara J., Fernandez de Paz J., et al. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double blind, multicenter clinical trial. J Hepatol 30 (1999) 1081-1089
29. Center S.A., Randolph J.F., Warner K.L., et al. The effects of S-adenosylmethionine on clinical pathology and redox potential in the red blood cell, liver and bile of clinically normal cats. J Vet Intern Med 19 (2005) 303-314
30. Center S.A., Warner K.L., McCabe J., et al. Evaluation of the influence of S-adenosylmethionine on systemic and hepatic effects of prednisolone in dogs. Am J Vet Res 66 (2005) 330-341
31. Webb C.B., Twedt D.C., Fettman M.J., et al. S-adenosylmethionine (SAMe) in a feline acetaminophen model of oxidative injury. J Feline Med Surg 38 (2003) 246-254
32. Wallace K.P., Center S.A., Hickford F.H., et al. S-adenosyl-L-methionine (SAMe) for the treatment of acetaminophen toxicity in a dog. J Am Anim Hosp Assoc 38 (2002) 246-254
33. Giulidori P., and Stramentinoli G. A radioenzymatic method of S-adenosyl-L-methionine determination in biological fluids. Anal Biochem 137 (1984) 217-220
34. Center S.A., Warner K., and Hollis E. Liver glutathione concentrations in dogs and cats with naturally occurring liver disease. Am J Vet Res 63 (2002) 1187-1197
35. Spee B., Arends B., van den Ingh T.S.G.A.M., et al. Copper metabolism and oxidative stress in chronic inflammatory and cholestatic liver diseases in dogs. J Vet Intern Med 20 (2006) 1085-1092
36. Zafarullah M., Li W.Q., Sylvester J., et al. Molecular mechanisms of N-acetylcysteine actions. Cell Mol Life Sci 60 (2003) 6-20
37. Kaya H., Sogut S., Duru M., et al. The protective effect of N-acetylcysteine against cyclosporine A induced hepatotoxicity in rats. J Appl Toxicol 28 (2008) 15-20
38. Santra A., Chowdhury A., Ghatak S., et al. Arsenic induced apoptosis in mouse liver is mitochondrial dependent and is abrogated by N-acetylcysteine. Toxicol Appl Pharmacol 220 (2007) 146-155
39. Wang H., Xu D.X., Lu J.W., et al. N-acetylcysteine attenuates lipopolysaccharide induced apoptotic liver damage in D-galactosamine sensitized mice. Acta Pharmacol Sin 28 (2007) 1803-1809
40. Menor C., Fernandez-Moreno M.D., Fueyo J.A., et al. Azathioprine acts upon rat hepatocyte mitochondria and stress activated protein kinases leading to necrosis: protective role of N-acetyl-L-cysteine. J Pharmacol Exp Ther 311 (2004) 668-676
41. Ytrebo L.M., Korvald C., Nedredal G.I., et al. N-acetylcysteine increases cerebral perfusion pressure in pigs with fulminant hepatic failure. Crit Care Med 29 (2001) 1989-1995
42. Harrison P.M., Wendon J.A., Gimson A.E., et al. Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure. N Engl J Med 324 (1991) 1852-1857
43. Jin X., Wang L., Wu H.S., et al. N-acetylcysteine inhibits activation of toll-like receptor 2 and 4 gene expression in the liver and lung after partial hepatic ischemia-reperfusion injury in mice. Hepatobiliary Pancreat Dis Int 6 (2007) 284-289
44. Smyrnoitis V., Arkadopoulos N., Kostopanagiotou G., et al. Attenuation of ischemic injury by N-acetylcysteine preconditioning of the liver. J Surg Res 129 (2005) 31-37
45. Fusai G., Glantzounis G.K., Hafez T., et al. N-acetylcysteine ameliorates the late phase of liver ischaemia/reperfusion injury in the rabbit with hepatic steatosis. Clin Sci (Lond) 109 (2005) 465-473
46. Baumann J., Ghosh S., Szakmany T., et al. Short-term effects of N-acetylcysteine and ischemic preconditioning in a canine model of hepatic ischemia-reperfusion injury. Eur Surg Res 41 (2008) 226-230
47. Yang Y.Y., Lee K.C., Huang Y.T., et al. Effect of N-acetylcysteine administration in hepatic microcirculation of rats with biliary obstruction. J Hepatol 49 (2008) 25-33
48. Kigawa H., Nakano K., Kumada, et al. Improvement of portal flow and hepatic microcirculatory tissue flow with N-acetylcysteine in dogs with obstructive jaundice produced by bile duct ligation. Eur J Surg 166 (2000) 77-84
49. Kortsalioudaki C., Taylor R.M., Cheeseman P., et al. Safety and efficacy of N-acetylcysteine in children with non-acetaminophen induced acute liver failure. Liver Transpl 14 (2008) 25-30
50. Lee W.M., Lorenzo R., Fontana R., et al. Intravenous N-acetylcysteine improves spontaneous survival in early stage non-acetaminophen acute liver failure. Hepatology 46 (2007) 268A
51. Hjelle J.J., and Grauer G.F. Acetaminophen-induced toxicosis in dogs and cats. J Am Vet Med Assoc 188 (1986) 742-746
52. Buck W.B., and Gonzalez J.M. Ibuprofen, aspirin and acetaminophen toxicosis and treatment in dogs and cats. Vet Hum Toxicol 40 (1998) 156-162
53. Aronson L.R., and Drobatz K. Acetaminophen toxicosis in 17 cats. J Vet Emerg Crit Care 6 (1996) 65-69
54. Ilkiw J.E., and Ratcliffe R.C. Paracetamol toxicity in a cat. Aust Vet J 64 (1987) 245-247
55. Paumgartner G. Medical treatment of cholestatic liver diseases: from pathobiology to pharmacological targets. World J Gastroenterol 12 (2006) 4445-4451
56. Rivard A.L., Steer C.J., Kren B.T., et al. Administration of tauroursodeoxycholic acid (TUDCA) reduces apoptosis following myocardial infarction in rat. Am J Chin Med 35 (2007) 279-295
57. Ramalho R.M., Viana R.J., Low W.C., et al. Bile acids and apoptosis modulation: an emerging role in experimental Alzheimer's disease. Trends Mol Med 14 (2008) 54-62
58. Bernardes-Silva C.F., Damiao A.O., Sipahi A.M., et al. Ursodeoxycholic acid ameliorates experimental ileitis counteracting intestinal barrier dysfunction and oxidative stress. Dig Dis Sci 49 (2004) 1569-1574
59. Ozcan U., Yilmaz E., Ozcan L., et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 313 (2006) 1137-1140
60. Sola S., Amaral J.D., Castro R.E., et al. Nuclear translocation of UDCA by the glucocorticoid receptor is required to reduce TGF-beta1-induced apoptosis in rat hepatocytes. Hepatology 42 (2005) 925-934
61. Weitzel C., Stark D., Kullman F., et al. Ursodeoxycholic acid induced activation of the glucocorticoid receptor in primary rat hepatocytes. Eur J Gastroenterol Hepatol 17 (2005) 169-277
62. Okan A., Astarcioglu H., Tankurt E., et al. Effect of ursodeoxycholic acid on hepatic steatosis in rats. Dig Dis Sci 47 (2002) 2389-2397
63. Paumgartner G. Ursodeoxycholic acid for primary biliary cirrhosis: treat early to slow progression. J Hepatol 39 (2003) 112-114
64. Gong Y., Huang Z., Christensen E., et al. Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses. Am J Gastroenterol 108 (2007) 1799-1807
65. Shi J., Wu C., Lin Y., et al. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials. Am J Gastroenterol 101 (2006) 1529-1538
66. Lindor K.D. Ursodiol for primary sclerosing cholangitis: Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 336 (1997) 691-695
67. Desmond C.P., Wilson J., Bailey M., et al. The benign course of liver disease in adults with cystic fibrosis and the effect of ursodeoxycholic acid. Liver Int 27 (2007) 1402-1408
68. Binder T., Salaj P., Zima T., et al. Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis in pregnancy. J Perinat Med 34 (2006) 383-391
69. Meyer D.J., Thompson M.B., and Senior D.F. Use of ursodeoxycholic acids in a dog with chronic hepatitis: effects on serum hepatic tests and endogenous bile acid compositions. J Vet Intern Med 11 (1997) 195-197
70. Nicholson B.T., Center S.A., and Randolph J.F. Effects of oral ursodeoxycholic acid in healthy cats on clinicopathological parameters, serum bile acids and light microscopic and ultrastructural features of the liver. Res Vet Sci 61 (1996) 258-262
71. Walter R., Dunn M.E., and d'Anjou M.-A. Nonsurgical resolution of gallbladder mucocele in 2 dogs. J Am Vet Med Assoc 232 (2008) 1688-1693
72. Milkiewicz P., Mills C.O., Roma M.G., et al. Tauroursodeoxycholate and S-adenosyl-L-methionine exert an additive ameliorating effect on taurolithocholate-induced cholestasis: a study in isolated rat hepatocyte couplets. Hepatology 29 (1999) 471-476
73. Polyak S.J., Morishima C., Shuhart M.C., et al. Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized Silymarin. Gastroenterology 132 (2007) 1925-1936
74. Campos R., Garrido A., Guerra R., et al. Silybin dehemisuccinate protects against glutathione depletion and lipid peroxidation induced by acetaminophen on rat liver. Planta Med 5 (1989) 417-419
75. Wang M., Grange L.L., and Tao J. Hepatoprotective properties of Silybum marianum herbal preparation on ethanol induced liver damage. Fitoterapia 67 (1996) 167-171
76. Muriel P., and Mourelle M. Prevention by silymarin of membrane alterations in acute CCl4 liver damage. J Appl Toxicol 10 (1990) 275-279
77. Paulova J., Dvorak M., Kolouch F., et al. Evaluation of the hepatoprotective and therapeutic effects of silymarin in liver damage experimentally produced with carbon tetrachloride in dogs. Vet Med (Praha) 35 (1990) 629-635
78. Boigk G., Stroedter L., Herbst H., et al. Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology 26 (1997) 643-649
79. Lieber C.S., Leo M.A., Cao Q., et al. Silymarin retards the progression of alcohol-induced hepatic fibrosis in baboons. J Clin Gastroenterol 37 (2003) 336-339
80. Sonnenbitchler J., Goldberg M., Hane L., et al. Stimulatory effect of silybin on the DNA synthesis in partially hepatectomized rat livers: nonresponse in hepatomo and other malignant cell lines. Biochem Pharmacol 20 (1986) 888-893
81. Silymarin as therapy of liver disease. Presented at a workshop sponsored by the National institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Center for Complementary and Alternative Medicine (NCCAM), and National Institute on Alcohol Abuse and Alcoholism (NIAAA). Bethesda (MD). Available at:. http://www2.niddk.nih.gov/NR/rdonlyres/0AECDEC8-10B4-47A1-A7BA0939D1050E53/0/DDICC_March_22_2004_workshop_summary.pdf Accessed March 22, 2004
82. Vogel G., Tuchweber B., Trost W., et al. Protection by silibinin against Amanita phalloides intoxication in beagles. Toxicol Appl Pharmacol 73 (1984) 355-362
83. Filburn C.R., Kettenacker R., and Griffin D.W. Bioavailability of a silybin-phosphatidylcholine complex in dogs. J Vet Pharmacol Ther 30 (2007) 132-138
84. Kidd P., and Head K. A review of the bioavailability and clinical efficacy of milk thistle phytosome: a silybin-phosphatidylcholine complex (Siliphos). Altern Med Rev 10 (2005) 193-203
85. Morazzoni P., Montalbetti A., and Malandrino S. Comparative pharmacokinetics of silipide and silymarin in rats. Eur J Drug Metab Pharmacokinet 18 (1993) 289-297
86. Webb C.B., Samber B.J., Gustafson D., et al. Bioavailability following oral administration of a silibinin-phosphatidylcholine complex in cats. J Vet Intern Med 22 (2008) 812A
87. Webb C.B., McCord K.W., and Twedt D.C. Oxidative stress and neutrophil function following oral supplementation of a silibinin-phosphatidylcholine complex in cats. J Vet Intern Med 22 (2008) 808A
88. Soden J.S., Devereaux M.W., Haas J.E., et al. Subcutaneous vitamin E ameliorates liver injury in an in vivo model of steatocholestasis. Hepatology 46 (2007) 485-495
89. Parola M., Leonarduzzi G., Biasi F., et al. Vitamin E dietary supplementation protects against carbon tetrachloride-induced chronic liver damage and cirrhosis. Hepatology 22 (1995) 1474-1481
90. Harrison S.A., Torgerson S., Hayashi P., et al. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 98 (2003) 2485-2490
91. Vajro P., Mandato C., Franzese A., et al. Vitamin E treatment in pediatric obesity-related liver disease: a randomized study. J Pediatr Gastroenterol Nutr 38 (2004) 48-55
92. Dufour J.F., Oneta C.M., Gonvers J.J., et al. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 4 (2006) 1537-1543
93. Look M.P., Gerard A., Rao G.S., et al. Interferon/antioxidant combination therapy for chronic hepatitis C: a controlled pilot trial. Antiviral Res 43 (1999) 113-122
94. Twedt D.C., Webb C.B., and Tetrick M.A. The effect of dietary vitamin E on the clinical laboratory and oxidant status of dogs with chronic hepatitis. J Vet Intern Med 17 (2003) 418A